A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/ oxaliplatin (FOLFOX4) regimen

E. Cecchin, M. D'Andrea, S. Lonardi, C. Zanusso, N. Pella, D. Errante, E. De Mattia, J. Polesel, F. Innocenti, G. Toffoli

Research output: Contribution to journalArticle

Abstract

The discovery of pharmacogenomic markers in colorectal cancer (CRC) could be setting-specific. FOLFOX4 is employed in the adjuvant and metastatic setting in CRC. This prospective study is aimed to validate in the adjuvant setting the pharmacogenomic markers of toxicity reported in the metastatic setting (that is, GSTP1-rs947894, and -rs1138272; GSTM1-null genotype; AGXT-rs4426527, -rs34116584 and del-74 bp), and to discover additional markers. CRC patients (n=144) treated with adjuvant FOLFOX4 were genotyped for 57 polymorphisms in 29 genes. Grade ≥2 neurotoxicity was associated (false discovery rate-adjusted q-value

Original languageEnglish
Pages (from-to)403-409
Number of pages7
JournalPharmacogenomics Journal
Volume13
Issue number5
DOIs
Publication statusPublished - Oct 2013

Keywords

  • colorectal cancer
  • FOLFOX4
  • neurotoxicity
  • pharmacogenomics

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Fingerprint Dive into the research topics of 'A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/ oxaliplatin (FOLFOX4) regimen'. Together they form a unique fingerprint.

  • Cite this